Efficacy and safety of once‐daily insulin degludec/insulin aspart compared with once‐daily insulin glargine in participants with Type 2 diabetes: a randomized, treat‐to‐target stud...

por Kumar, S., Jang, H. C., Demirağ, N. G., Skjøth, T. V., Endahl, L., Bode, B.
Publicado 2016

Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co‐formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomiz...

por Rodbard, H. W., Cariou, B., Pieber, T. R., Endahl, L. A., Zacho, J., Cooper, J. G.
Publicado 2016

Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials

por Ratner, R E, Gough, S C L, Mathieu, C, Del Prato, S, Bode, B, Mersebach, H, Endahl, L, Zinman, B
Publicado 2013